Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1997 1
2001 1
2005 1
2007 1
2008 3
2009 5
2010 2
2013 1
2014 3
2016 2
2017 1
2019 1
2020 1
2021 2
2022 4
2023 2
2024 1
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA.
Shadman M, Munir T, Robak T, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Šimkovič M, Österborg A, Laurenti L, Walker PA, Opat SS, Ciepluch H, Greil R, Hanna M, Tani M, Trněný M, Brander D, Flinn IW, Grosicki S, Verner E, Tedeschi A, de Guibert S, Tumyan G, Laribi K, García-Marco JA, Li JY, Tian T, Liu Y, Korolkiewicz R, Szeto A, Tam CS, Jurczak W. Shadman M, et al. Among authors: opat ss. J Clin Oncol. 2025 Mar;43(7):780-787. doi: 10.1200/JCO-24-02265. Epub 2024 Dec 8. J Clin Oncol. 2025. PMID: 39647999 Free PMC article. Clinical Trial.
Zanubrutinib in the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies.
Tam CS, Anderson MA, Simkovic M, Ghia P, Flinn IW, Laribi K, Opat SS, Cull G, Munir T, Österborg A, Tedeschi A, Wang MY, Szeto AH, Allewelt H, Salmi T, Li J, Xu L, Wu K, Vezan R, Shadman M, Brown JR. Tam CS, et al. Among authors: opat ss. Blood Adv. 2025 Aug 19:bloodadvances.2025015986. doi: 10.1182/bloodadvances.2025015986. Online ahead of print. Blood Adv. 2025. PMID: 40829104
Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia.
Heyman BM, Opat SS, Wahlin BE, Dimopoulos MC, Castillo JJ, Tedeschi A, Tam CS, Buske C, Owen RG, Leblond V, Trotman J, Barnes G, Chan WY, Schneider J, Allewelt H, Cohen A, Matous JV. Heyman BM, et al. Among authors: opat ss. Blood Adv. 2025 Feb 25;9(4):722-728. doi: 10.1182/bloodadvances.2024014115. Blood Adv. 2025. PMID: 39626287 Free PMC article. Clinical Trial.
Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study.
García-Sanz R, Owen RG, Jurczak W, Dimopoulos MA, McCarthy H, Cull G, Opat SS, Castillo JJ, Kersten MJ, Wahlin BE, Grosicki S, Prathikanti R, Tian T, Allewelt H, Cohen AC, Tam CS. García-Sanz R, et al. Among authors: opat ss. Blood Adv. 2025 Dec 23;9(24):6538-6546. doi: 10.1182/bloodadvances.2024015596. Blood Adv. 2025. PMID: 40924923 Clinical Trial.
Oxidative haemolysis due to 'poppers'.
Shortt J, Polizzotto MN, Opat SS, Cole-Sinclair MF. Shortt J, et al. Among authors: opat ss. Br J Haematol. 2008 Jul;142(3):328. doi: 10.1111/j.1365-2141.2008.07150.x. Epub 2008 May 8. Br J Haematol. 2008. PMID: 18477042 No abstract available.
Bortezomib-based antibody depletion for refractory autoimmune hematological diseases.
Ratnasingam S, Walker PA, Tran H, Kaplan ZS, McFadyen JD, Tran H, Teh TC, Fleming S, Catalano JV, Chunilal SD, Johnston A, Opat SS, Shortt J. Ratnasingam S, et al. Among authors: opat ss. Blood Adv. 2016 Nov 22;1(1):31-35. doi: 10.1182/bloodadvances.2016001412. eCollection 2016 Nov 29. Blood Adv. 2016. PMID: 29296693 Free PMC article.
Associations between early-life growth pattern and body size and follicular lymphoma risk and survival: a family-based case-control study.
Odutola MK, van Leeuwen MT, Turner J, Bruinsma F, Seymour JF, Prince HM, Milliken ST, Hertzberg M, Trotman J, Opat SS, Lindeman R, Roncolato F, Verner E, Harvey M, Tiley C, Underhill CR, Benke G, Giles GG, Vajdic CM. Odutola MK, et al. Among authors: opat ss. Cancer Epidemiol. 2022 Oct;80:102241. doi: 10.1016/j.canep.2022.102241. Epub 2022 Sep 1. Cancer Epidemiol. 2022. PMID: 36058036
30 results